logo-loader
viewPreveCeutical Medical Inc

PreveCeutical develops proprietary method for extracting cannabinoids for Sol-gel

PreveCeutical Medical Inc. (CSE:PREV) CEO and President Stephen Van Deventer joined Steve Darling in the Vancouver studio of Proactive Investors to talk about the companies recent news that they had successfully optimized the conditions for extracting cannabinoids from one of its cannabis strains and developed a proprietary method for the accurate measurement of cannabinoids.

Van Deventer also shared details of their duel gene therapy program that deals with diabetes and obesity.
 

Quick facts: PreveCeutical Medical Inc

Price: 0.02 CAD

CSE:PREV
Market: CSE
Market Cap: $7.93 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc named herein, including the promotion by the Company of PreveCeutical Medical Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

PreveCeutical prepares for the final stage of their Sol-Gel program

PreveCeutical (CNSX:PREV) Chief Research Officer Dr Harry Parekh joined Steve Darling from Proactive Investors Vancouver to talk about the companies progress in the development of their sol-gel. Parekh telling proactive the next step they are undertaking with human tissue. He also talked...

on 27/4/19

2 min read